New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...

Elias Jabbour, MD, is a board-certified hematologist-oncologist and internationally recognized leukemia specialist. He is a Professor of Medicine and Chief of the Acute Lymphoblastic Leukemia (ALL) ...

Hematologist-oncologists are doctors who specialize in treating blood cancers such as acute lymphoblastic leukemia (ALL). ALL is a rare, rapidly progressing cancer of the blood and bone marrow. The ...

Every year around St. Patrick’s Day, a nonprofit organization dedicated to funding research to find cures for childhood cancers hosts a head-shaving event known as "St. Baldrick’s." On Thursday, ...

Scientists from the Children’s Hospital of Philadelphia (CHOP) report that they have discovered the underlying biology that identifies a subset of patients with acute lymphoblastic leukemia who have a ...

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

A new cell therapy, targeting CD7 on leukemia cells, gives a potentially effective treatment for patients with T-cell acute lymphoblastic leukemia (T-ALL) who have exhausted all standard treatment ...

HealthDay News — In guidelines issued by the American Society of Hematology and published online February 11 in Blood Advances, recommendations are presented for frontline management of acute ...